Press Releases

Appointment

Our website is currently being updated and you may experience some limited functionality at this time.

Home

About

Press Releases

Proaxsis

ProAxsis CEO to present at Biotrinity 2016

ProAxsis appoints experienced Sales and Marketing Manager

“ProActive Investors UK” interviews David Ribeiro

Dr Kelly Moffitt joins ProAxsis team

ProAxsis to present at 2016 American Thoracic Society Conference

ProAxsis team to attend BIO 2016

ProAxsis builds market presence

ProAxsis featured in Business Eye

ProAxsis CEO to present at Biotech in Europe

ProAxsis gains CE Mark for Active Neutrophil Elastase Immunoassay

ProAxsis receives Royal visit

ProAxsis to present at 2016 North American Cystic Fibrosis Conference

ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016

ProteaseTag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis

ProAxsis gains backing of Innovate UK

ProAxsis CEO to present update at Bio-Europe Spring

ProAxsis abstracts at 2017 American Thoracic Society Conference

ProAxsis successfully licenses additional intellectual property from The Queen’s University of Belfast

ProAxsis technology highlighted in AJRCCM editorial

ProAxsis CEO to present at Anglonordic Conference

ProAxsis’ Active Neutrophil Elastase Immunoassay highlighted in Stanford University trial

ProAxsis gains further support from Innovate UK

ProAxsis registers European CE Mark for first neutrophil elastase point-of-care test

ProAxsis abstracts at 2017 European Respiratory Society Conference

ProAxsis signs partnership with a large US based biotechnology company

ProAxsis appoints first distributor for NE Immunoassay

ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference

ProAxsis to test ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease at National Jewish Health

ProAxsis provides update on commercialisation progress

NEATSTIK®ProAxsis abstracts at 2017 British Thoracic Society Winter Meeting

ProAxsis Launches ProteaseTag® Active Plasmin Immunoassay following CE Mark registration

ProAxsis reports first NEATstik® sale

New opportunity for Early Stage Researcher at Queen’s University Belfast

ProAxsis Presenting New Data on NEATstik and New High Sensitivity Neutrophil Elastase Immunoassay at ATS 2018

ProAxsis receives further backing from Invest Northern Ireland under EU investment

ProAxsis wins Innovative Business of the Year Award

ProAxsis presenting further data at COPD 11 Conference

ProAxsis enhances portfolio with new CE Marked Immunoassay

ProAxsis presenting new data at 2018 European Respiratory Society Conference

ProAxsis assays selected for inclusion in major new ERS-funded study

ProAxsis to present data on novel immunoassay at 2018 British Thoracic Society Winter Meeting

New data demonstrates high potential of NEATstik® as a rapid point-of-care monitoring tool for lung diseases

ProAxsis welcomes Professor Stephen Smith as new Chairman

ProAxsis supports next generation of scientists

ProAxsis shortlisted for Small Business of the Year Award

ProAxsis announces new appointments

ProAxsis and Ulster University initiate new partnership

ProAxsis and the Connected Health Innovation Centre launch new partnership

ProAxsis investing in R&D to create new diagnostic tests for chronic human diseases

ProAxsis accelerates work on inflammatory biomarkers associated with COVID-19

NetScientific acquires 100% control of portfolio company ProAxsis Limited

ProAxsis Limited appoints distributor for key North America region

ProAxsis Limited recognised as Gold Level Innovator by Innovate NI

ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19

ProAxsis Limited appoints first distributor for DACH region

ProAxsis Limited enters licensing agreement with top Swiss University as it continues to develop novel new products in the fight against fractures and other metabolic bone diseases

ProAxsis Ltd CEO Update Report – End Q4 2021

ProAxsis signs global in-licensing agreement with AstraZeneca for COVID-19 serology test

ProAxsis announces commercial team expansion

Aptamer Group and ProAxsis Limited enter partnership to improve global logistics and stability of diagnostic tests

ProAxsis presents exciting new data at the ERS International Congress 2021

ProAxsis expands COVID-19 research programme with new award

ProAxsis CEO attending DxPx conference

ProAxsis releases new NEATstik® data at the Irish Thoracic Society Conference 2021

ProAxsis establishes new internal Finance team

ProAxsis expands inflammatory biomarker research via new partnership with Queen’s University Belfast

ProAxsis enhances availability of product portfolio in Asia via new partnership with Kyberlife

ProAxsis signs global in-licensing agreement

ProAxsis Ltd CEO Update Report – May 2021

Equipping Researchers Lab In The Developing

Patient Experience Better Health Wishes

ProAxsis announces “impressive” results in Performance Evaluation of COVID-19 antibody test

Belfast Telegraph Awards

ProAxsis’ Protease Tag® NE Immunoassay highlighted at BTS 2016

Protease Tag® Active Neutrophil Elastase Immunoassay used to predict future risk of exacerbation in bronchiectasis

ProAxsis announces additional key appointments

Measuring bone health with a new innovation for patients at high risk of osteoporotic fractures

Press release from University of Dundee (re bronchiestasis) May2022

Data presentation at ERS

Stanford University study (Bergener) 2017 NE associated with Pf Bacteriophage with higher levels of P.Aeruginosa

ProAxsis and Singapore based Kyberlife announce partnership

ProAxsis and Queen’s University of Belfast secure a second licensing agreement for exclusive intellectual property rights ProteaseTag® technology

ProAxsis signs partnership agreement with US based Biotechnology company to develop two key respiratory proteases, utilizing ProteaseTag® technology, a platform technology that allows any protease to be targeted

ProAxsis announces collaboration with Dr. Gunnar Schroeder and Prof. Cliff Taggart from School of Medicine, Dentistry and Biomedical Science at Queen’s University Belfast as part of the Horizon 2020-funded SPaRK Programme.

ProAxsis has formed a new partnership with Ulster University, the largest university in Northern Ireland to collaborate on an initial 12-week project with the Eastern Corridor Medical Engineering (ECME) supporting the development of relevant platform technologies

ProAxsis announces a collaborative 12-month project with Northern Ireland Connected Health Innovation Centre (CHIC) based at Ulster University to focus on the development of a quantitative lateral flow device designed to monitor the ongoing clinical status of patients with respiratory diseases such as bronchiectasis, cystic fibrosis and COPD

ProAxsis announced a global licensing agreement with the collaboration of the University of Geneva and the University Hospital of Geneva on a higly novel assay for Cathespin K-dependent periostin cleavage product as a biomarker of bone fragility related to disorders such as osteoporosis.

ProAxsis announces it has entered into an exclusive licensing agreement with AstraZeneca and will complete the validation and global commercialization of a SARS-CoV-2 (the virus associated with COVID-19) serology ELISA test. In AstraZeneca will provide access to intellectual property and technical know-how, and in return will receive an undisclosed royalty fee on future Global net sales of the assay.

ProAxsis and Aptamer Group, the developer of custom affinity ligands to enable the life science industry through its proprietary OptimerTM platform announce a partnership to develop Optimer ligands for ProAxsis’s diagnostic assays. Aptamer Group will develop validated Optimer ligands against critical targets for ProAxsis’s diagnostic assays.(August 2021)

ProAxsishosted His Royal Highness, the Duke of York, at their new laboratory facilities within the Concourse III building at Catalyst Inc. Prince Andrew, who is Patron of Catalyst Inc., spent time meeting the team as well as finding out more details about the company’s novel ProteaseTag® technology, which allows for the detection and measurement of active protease biomarkers of disease.

ProAxsis ProAxsis is further expanding its ProteaseTag® technology platform, via a project co-funded by the UK’s innovation agency, Innovate UK. ProAxsis has already registered a CE Mark in Europe for its ProteaseTag® Active Neutrophil Elastase Immunoassay as a biomarker of infection and inflammation in patients with chronic respiratory diseases such as bronchiectasis, COPD and cystic fibrosis. The company has now been successful with a recent application to theBioMedical Catalyst competition.

ProAxsis received an Invest NI Grant for Research and Development, supporting the company to develop new products using its innovative ProteaseTag® technology. The grant is part financed under the European Union’s Investment for Growth and Jobs Programme for Northern Ireland. The project, entitled “The development of ProteaseTags® for deubiquitinases (DUBs): innovative tools for biomarker identification and drug discovery in oncology”, will be over the next 12 months and aims to allow the design and synthesis of peptide-based inhibitors for the DUBs family, implemented followed by an assessment of their incorporation in to prototype activity-based immunoassay formats. (June 2018)

ProAxsis declared as the “Innovative Business of the Year” at the Business Eye First Trust Awards (BEFTAs) for small businesses in Northern Ireland. The awards ceremony took place May 31st in Belfast, and was compered by the UTV newsreader and Northern Ireland correspondent for ITV, Marc Mallett. Over 50 Northern Irish businesses were shortlisted across the 14 award categories. The ProAxsis team were announced as the Innovative Business of the Year by Tina McKenzie, the Chair of the Federation of Small Businesses NI, who sponsored the innovation category. (June 2018)

ProAxsis announces that two of its products, the ProteaseTag® Active NE Immunoassay, and NEATstik®, the first test to enable measurement of active neutrophil elastase at point-of-care, have been selected for inclusion in a major upcoming clinical trial. The BRIDGE study is a 3-year collaborative study, funded by the European Respiratory Society (ERS), in which1000 patients with bronchiectasis across Europe will be recruited and will have multiple assessments including microbiome,proteomics, detailed phenotyping and imaging. The study will explore novel biomarkers and demonstrate what they can add to clinical practice. (Sept 2018)

Biotech Showcase, BIO Partnering at JPM San Francisco, CA 9-11 January 2023

IVD Clinical & Regulatory Affairs Conference San Diego, CA 7-8 February 2023

3rd European BronchiectasisMilan, Italy 23-25 February 2023

AAAAI (American Academy of Allergy, Asthma and Immunology) Annual Meeting San Antonio, TX 24-27 February 2023

Lung Science Conference European Respiratory Society Estoril, Portugal 9-12 March 2023

Texas Lung Cancer Conference Austin, TX 30March – 1April 2023

Association of Medical Diagnostics Manufacturers IVD Regulatory Meeting Bethesda, MD 19-20 April,2023

American Thoracic Society Annual Meeting Washington DC, 19-24 May 2023

Press Releases

About

Press Releases

Proaxsis

Subscribe & Follow us

Subscribe for updates & our newsletter

Contact us for personalized support

Quick Links

Contact Info

Quick Links

Other Pages

Contact Info